What oral and intravenous antibiotic regimens are recommended for treating lower extremity cellulitis, including considerations for penicillin allergy, MRSA risk factors, and severe disease?

Antibiotic Choice for Cellulitis of Lower Extremity

For outpatient nonpurulent lower extremity cellulitis, start with oral β-lactam antibiotics targeting β-hemolytic streptococci (cephalexin 500 mg four times daily or dicloxacillin 500 mg four times daily for 5-10 days), and only add MRSA coverage if the patient fails to respond or has systemic toxicity. 1

Clinical Approach: Purulent vs. Nonpurulent

The critical first step is determining whether the cellulitis is purulent (with drainage/exudate but no drainable abscess) or nonpurulent (no purulent drainage, exudate, or abscess). This distinction drives antibiotic selection.

Nonpurulent Cellulitis (Most Common)

• First-line oral therapy: Target β-hemolytic streptococci 1, 2

  • Cephalexin 500 mg four times daily (preferred for convenience) 3
  • Dicloxacillin 500 mg four times daily 3
  • Amoxicillin 875 mg twice daily (alternative)

• Duration: 5-10 days, individualized to clinical response 1

• When to add MRSA coverage:

  • Patient fails to respond to β-lactam therapy after 48-72 hours 1
  • Systemic toxicity present (fever, tachycardia, hypotension) 1
  • Known MRSA colonization or prior MRSA infection 4

Important caveat: Despite rising community-acquired MRSA rates, empirical MRSA coverage for nonpurulent cellulitis is NOT routinely recommended because β-hemolytic streptococci remain the predominant pathogen 1, 5. The IDSA guidelines explicitly state "the role of CA-MRSA is unknown" in nonpurulent cellulitis 1.

Purulent Cellulitis

• Empirical MRSA coverage is mandatory 1, 2

• Oral options:

  • Clindamycin 300-450 mg three times daily (covers both streptococci and MRSA) 1, 3
  • TMP-SMX 1-2 double-strength tablets twice daily PLUS amoxicillin 875 mg twice daily (TMP-SMX alone lacks streptococcal coverage) 1, 3
  • Doxycycline 100 mg twice daily PLUS amoxicillin 1, 3
  • Linezolid 600 mg twice daily (expensive, reserve for resistant cases) 1, 3

• Duration: 5-10 days 1

Critical pitfall: TMP-SMX and tetracyclines do NOT adequately cover β-hemolytic streptococci, so they must be combined with a β-lactam unless using clindamycin or linezolid alone 1, 3.

Penicillin Allergy Considerations

• Non-severe allergy (rash only): Use cephalexin or cefazolin (cross-reactivity risk <2%) 3, 6
• Severe/immediate hypersensitivity (anaphylaxis):
  • Oral: Clindamycin 300-450 mg three times daily 3
  • IV: Vancomycin 15-20 mg/kg every 8-12 hours 3

Recent evidence shows cephalosporins are safely prescribed in patients with penicillin allergy labels when cross-reactivity alerts are removed 6.

Hospitalized/Severe Disease

For patients requiring hospitalization with complicated SSTI (deeper infection, systemic illness, comorbidities, immunosuppression):

Intravenous Options (7-14 days):

MRSA-active agents (empirical therapy pending cultures):

• Vancomycin 15-20 mg/kg every 8-12 hours IV (drug of choice, A-I evidence) 1, 3
• Linezolid 600 mg IV/PO twice daily (A-I evidence, allows early IV-to-oral switch) 1, 3
• Daptomycin 4 mg/kg IV once daily (A-I evidence) 1, 3
• Ceftaroline 600 mg IV twice daily (newer option) 3, 7
• Dalbavancin 1500 mg IV single dose (long-acting lipoglycopeptide) 7

For nonpurulent cellulitis in hospitalized patients:

• Cefazolin 1 g IV every 8 hours may be considered initially, with switch to MRSA-active therapy if no clinical response 1

IV-to-Oral Switch Criteria:

• Clinical stability achieved (afebrile, decreasing erythema/swelling) 7
• Typically after 48-72 hours of IV therapy 8
• Oral bioavailability excellent with linezolid, clindamycin, TMP-SMX, doxycycline 7

Key evidence: A randomized trial demonstrated oral cephalexin was non-inferior to IV cefazolin for uncomplicated cellulitis, with mean time to cessation of progression 1.29 days (oral) vs 1.78 days (IV) 8. This supports early oral therapy or even initial oral treatment for appropriate patients.

MRSA Risk Factors

Consider empirical MRSA coverage if patient has:

• Athletes, military recruits, prisoners 4
• Men who have sex with men 4
• IV drug users 4
• Long-term care facility residents 4
• Prior MRSA infection/colonization 4
• Children in daycare settings 4
• Purulent drainage present 1

In MRSA-prevalent areas (>60% of S. aureus isolates), empirical MRSA coverage may be justified even for nonpurulent cellulitis 9. A Hawaii study showed TMP-SMX had 91% success vs 74% for cephalexin in a high MRSA prevalence setting 9.

Pediatric Considerations

• Tetracyclines contraindicated <8 years of age 1, 3
• Hospitalized children with complicated SSTI: Vancomycin 40 mg/kg/day in 4 divided doses IV 1
• Alternative if stable: Clindamycin 10-13 mg/kg/dose IV every 6-8 hours (if local clindamycin resistance <10%) 1
• Linezolid dosing:

  • 12 years: 600 mg twice daily 1

  • <12 years: 10 mg/kg every 8 hours 1

Agents to AVOID

• Rifampin as monotherapy or adjunctive therapy (A-III recommendation against) 1, 2
• Fluoroquinolones (not recommended for cellulitis, reserved for other indications)

Treatment Duration

• Outpatient cellulitis: 5-10 days 1, 2, 3
• Hospitalized/complicated SSTI: 7-14 days 1, 3
• Adjust based on clinical response: Continue until erythema, warmth, and swelling are resolving

Culture Recommendations

Obtain cultures from purulent drainage if:

• Patient treated with antibiotics 1
• Severe local infection or systemic illness 1
• Failed initial treatment 1
• Concern for outbreak 1

Blood cultures have low yield (<5%) in uncomplicated cellulitis and are not routinely recommended 4.